CCR2 and COVID-19: The CCR5/CCR2b small molecule antagonist cenicriviroc reduces SARS-CoV-2 replication in vitro (Okamoto et al., 2020), and a phase 2 trial is testing the effectiveness of cenicriviroc to reduce the severity of COVID-19 (ClinicalTrials.gov Identifier: NCT04500418).